title: Urological medical oncology: land of opportunity.
abstract: Robert Jones speaks to Francesca Lake, Managing Commissioning Editor. Robert completed his PhD in molecular biology at the Beatson Institute for Cancer Research (Glasgow, UK) and is currently the senior lecturer in medical oncology at the University of Glasgow (UK) and a consultant at the Beatson West of Scotland Cancer Centre (Glasgow, UK). He is involved in the management of prostate, bladder and kidney cancers in the clinic and performs collaborative translational research with researchers from the Beatson Institute. He also manages Phase I, II and III trials in the urological cancer field, and is Chief Investigator of the TOUCAN and PLUTO trials (urothelial cancer), SAPROCAN and MAdCaP trials (prostate cancer), and the UK component of the ASPEN trial (renal cell carcinoma). Recently, he has been involved in the COMPARZ trial, which compared pazopanib with sunitinib in renal cell carcinoma patients. He is director of the Glasgow Cancer Research UK Clinical Trials Unit and is an active member of the UK National Cancer Research Institute Clinical Studies Groups in urology.
authors: Robert
authors: R
authors: Jones
mesh_terms: D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D035843:Biomedical Research; D017326:Clinical Trials, Phase III as Topic; D006801:Humans; D007191:Indazoles; D008495:Medical Oncology; D011743:Pyrimidines / Q000009:adverse effects / Q000627:therapeutic use; D012606:Scotland; D013449:Sulfonamides / Q000009:adverse effects / Q000627:therapeutic use; D014571:Urologic Neoplasms / Q000188:drug therapy*; D014572:Urology
chemical_list: D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D007191:Indazoles; D011743:Pyrimidines; D013449:Sulfonamides; C516667:pazopanib